Silencing LMNB1 Contributes to the Suppression of Lung Adenocarcinoma Development

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. doi:10.3322/caac.2155130620402
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Petersen I, Warth A. Lung cancer: developments, concepts, and specific aspects of the new WHO classification. J Cancer Res Clin. 2016;142:895–904. doi:10.1007/s00432-015-2004-4
   PubMed Web of Science ®Google Scholar
• Walder D, O’Brien M. Looking back and to the future: are we improving ‘cure’ in non-small cell lung cancer? Eur J Cancer. 2017;75:192–194. doi:10.1016/j.ejca.2017.01.00628236771
   PubMed Web of Science ®Google Scholar
• Barr Kumarakulasinghe N, NV Zanwijk, RA Soo. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). Respirology. 2015;20:370–378. doi:10.1111/resp.1249025689095
   PubMed Web of Science ®Google Scholar
• Rosell R, Karachaliou N. Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer. Lancet Oncol. 2018;19:e126. doi:10.1016/S1470-2045(18)30071-829508751
   PubMed Web of Science ®Google Scholar
• Sgambato A, Casaluce F, Maione P, Gridelli C. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors. Expert Rev Anticancer. 2018;18:71–80. doi:10.1080/14737140.2018.1412260
   PubMed Web of Science ®Google Scholar
• Wang L, Ma Q, Yao R, Liu J. Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer. Int Immunopharmacol. 2020;79:106088. doi:10.1016/j.intimp.2019.10608831896512
   PubMed Web of Science ®Google Scholar
• Cremer T, Cremer M. Chromosome territories. CSH Perspect Biol. 2010;2:a3889.
   PubMed Web of Science ®Google Scholar
• Dechat T, Pfleghaar K, Sengupta K, et al. Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Gene Dev. 2008;22(7):832–853. doi:10.1101/gad.165270818381888
   PubMed Web of Science ®Google Scholar
• Gigante CM, Dibattista M, Dong FN, et al. Lamin B1 is required for mature neuron-specific gene expression during olfactory sensory neuron differentiation. Nat Commun. 2017;8(1):15098. doi:10.1038/ncomms1509828425486
   PubMed Web of Science ®Google Scholar
• Camps J, Erdos MR, Ried T. The role of lamin B1 for the maintenance of nuclear structure and function. Nucleus-Phila. 2015;6(1):8–14. doi:10.1080/19491034.2014.1003510
   PubMed Web of Science ®Google Scholar
• Lukášová E, Kovařík A, Kozubek S. Consequences of Lamin B1 and Lamin B receptor downregulation in senescence. Cells-Basel. 2018;7(2):11. doi:10.3390/cells7020011
   PubMed Web of Science ®Google Scholar
• Radspieler MM, Schindeldecker M, Stenzel P, et al. Lamin-B1 is a senescence-associated biomarker in clear-cell renal cell carcinoma. Oncol Lett. 2019;18(3):2654–2660. doi:10.3892/ol.2019.1059331402955
   PubMed Web of Science ®Google Scholar
• Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19.26667336
   PubMed Web of Science ®Google Scholar
• Network TCGA. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–550.25079552
   PubMed Web of Science ®Google Scholar
• Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. 2018;9(2):117. doi:10.1038/s41419-017-0063-y29371589
   PubMed Web of Science ®Google Scholar
• Wu SG, Shih JY. Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17(1):38. doi:10.1186/s12943-018-0777-129455650
   PubMed Web of Science ®Google Scholar
• Nan X, Xie C, Yu X, Liu J. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget. 2017;8(43):75712–75726. doi:10.18632/oncotarget.2009529088904
   PubMedGoogle Scholar
• Frezzetti D, Gallo M, Maiello MR, et al. VEGF as a potential target in lung cancer. Expert Opin Ther Tar. 2017;21(10):959–966. doi:10.1080/14728222.2017.1371137
   PubMed Web of Science ®Google Scholar
• Ke EE, Wu YL. EGFR as a pharmacological target in EGFR -mutant non-small-cell lung cancer: where do we stand now? Trends Pharmacol Sci. 2016;37(11):887–903. doi:10.1016/j.tips.2016.09.00327717507
   PubMed Web of Science ®Google Scholar
• Forde PM, Ettinger DS. Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer. 2013;13(6):745–758. doi:10.1586/era.13.47
   PubMed Web of Science ®Google Scholar
• Chen C, Sang Y, Liu L, Feng Z, Liang Z, Pei X. THAP7 promotes cell proliferation by regulating the G1/S phase transition via epigenetically silencing p21 in lung adenocarcinoma. Onco Targets Ther. 2019;12:5651–5660. doi:10.2147/OTT.S20890831372002
   PubMed Web of Science ®Google Scholar
• Ahmmed B, Khan MN, Nisar MA, et al. Tunicamycin enhances the suppressive effects of cisplatin on lung cancer growth through PTX3 glycosylation via AKT/NF-κB signaling pathway. Int J Oncol. 2019;54:431–442. doi:10.3892/ijo.2018.465030483742
   PubMed Web of Science ®Google Scholar
• Izdebska M, Gagat M, Grzanka A. Overexpression of lamin B1 induces mitotic catastrophe in colon cancer LoVo cells and is associated with worse clinical outcomes. Int J Oncol. 2018;52:89–102. doi:10.3892/ijo.2017.418229115590
   PubMed Web of Science ®Google Scholar
• Yang Z, Wang Z, Zhao T. Huaier suppresses proliferative and metastatic potential of prostate cancer PC3 cells via downregulation of Lamin B1 and induction of autophagy. Oncol Rep. 2018;39:3055–3063. doi:10.3892/or.2018.635829658595
   PubMed Web of Science ®Google Scholar
• Jia Y, Vong JS, Asafova A, et al. Lamin B1 loss promotes lung cancer development and metastasis by epigenetic derepression of RET. J Exp Med. 2019;216:1377–1395. doi:10.1084/jem.2018139431015297
   PubMed Web of Science ®Google Scholar
• Garvalov BK, Muhammad S, Dobreva G. Lamin B1 in cancer and aging. Aging. 2019;11(18):7336–7338. doi:10.18632/aging.10230631541995
   PubMedGoogle Scholar
• Wang Q, Chen X, Hay N. Akt as a target for cancer therapy: more is not always better (lessons from studies in mice). Brit J Cancer. 2017;117(2):159–163. doi:10.1038/bjc.2017.15328557977
   PubMed Web of Science ®Google Scholar
• Żuryń A, Litwiniec A, Safiejko-Mroczka B, Klimaszewska-Wiśniewska A, Gagat M, Krajewski A, Gackowska L, Grzanka D. The effect of sulforaphane on the cell cycle, apoptosis and expression of cyclin D1 and p21 in the A549 non-small cell lung cancer cell line. Int J Oncol. 2016;48(6):2521. doi:10.3892/ijo.2016.344427035641
   PubMed Web of Science ®Google Scholar
• Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non–small-cell lung cancer. New Engl J Med. 2017;376(22):2109–2121. doi:10.1056/NEJMoa161628828445112
   PubMed Web of Science ®Google Scholar